RecruitingNot ApplicableNCT05814094

Red Blood Cell Transfusion in ECMO - A Feasibility Trial

Sponsor

Australian and New Zealand Intensive Care Research Centre

Enrollment

120 participants

Start Date

Sep 20, 2023

Study Type

INTERVENTIONAL

Conditions

Disability Physical Cognitive Ability, General Extracorporeal Membrane Oxygenation Complication Functional Status Blood Loss Anemia

Summary

Extracorporeal Membrane Oxygenation (ECMO) is an invasive and resource intense treatment used to support critically ill patients who have suffered severe cardiac arrest, cardiac failure or respiratory failure (including severe cases of COVID-19). ECMO acts as a mechanical circulatory support temporarily replacing the function of the heart or lungs by oxygenating blood and removing carbon dioxide, allowing time for these organs to recover. Many critically ill patients, including those on ECMO, have an increased risk of bleeding and reduced production/increased destruction of red blood cells (RBCs). This can lead to anaemia (haemoglobin levels \<120 g/l), a condition where the body lacks enough healthy RBCs to carry enough oxygen to the body's tissues. Therefore, patients on ECMO frequently require RBC transfusion, with clinicians having to decide if administering an RBC transfusion (with its associated risks) is higher than tolerating complications of anaemia. ROSETTA is a feasibility study that aims to determine the safety and feasibility of randomizing patients on ECMO to a restrictive RBC transfusion strategy (maintain Hb concentration above 70g/L) or to a more liberal transfusion strategy (maintain Hb concentration above 90g/L). Feasibility is defined as the ability to achieve a mean separation of at least 10g/L between the average lowest daily haemoglobin values in the two study groups.

Eligibility

Min Age: 18 Years

Inclusion Criteria2

Patients receiving ECMO
Age: 18 years or older

Exclusion Criteria9

Contraindication to RBC transfusion (including known patient preference)
Limitations of care put in place either through patient wishes or the treating medical teams
ECMO treatment for more than 12 hours. The start of ECMO is defined as the time of initiation of extracorporeal blood flow unless ECMO was initiated during a surgical intervention in which case the start is defined as the arrival time into the initial ICU.
The treating physician anticipates that ECMO treatment will cease before the end of tomorrow
Where the treating physician deems the study is not in the patient's best interest
Where the treating physician has concern regarding patient ability to tolerate restrictive or liberal transfusion trigger thresholds
Patients actively listed for a solid organ transplant
Patients who are suspected or confirmed to be pregnant
Previous ECMO treatment during the same hospital admission

Print for Your Doctor

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERRed Blood Cell Transfusion

Following randomisation, if a patient's Hb concentration reads ≤ 70g/L, one unit of RBC will be transfused within 12 hours of the result becoming available. Additional units can be prescribed if required to raise the Hb concentration to above 70g/L. A transfusion above the restrictive threshold of 70g/L is discouraged.

OTHERRed Blood Cell Transfusion

Following randomisation, if a patient's Hb concentration reads ≤ 90g/L, one or more units of RBC will be transfused in order to raise the Hb concentration to greater than 90g/L within 12 hours of the result becoming available. A decision not to transfuse below the threshold of 90g/L is discouraged.